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(SOC) vs SOC alone in the US health care setting. The objective of this analysis is to 
assess the cost-effectiveness of RDN in patients with TR-HTN from the Australian 
payer perspective. Methods: Geisler methods were largely retained but life tables, 
resource use, costs and discount rates were revised to reflect Australian parameters. 
Importantly, the treatment effect of RDN was based on a meta-analysis of all studies 
(regardless of catheter used) enrolling TR-HTN patients (SBP ≥ 160 mmHg despite 
> 3 anti-hypertensive drugs including a diuretic). The model consisted of 30 health 
states and employed multivariate risk equations from large-scale cohort studies 
to calculate transition probabilities of events and event mortality. Discounted (5%) 
costs and outcomes were calculated over a lifetime horizon. Results: The weighted 
mean decrease in office-based SBP over 6 months was -28.1 mmHg (95% CI: -24.5 
to -31.6). The RDN procedure cost ($10,724.22) was partially offset by lower event 
costs – primarily through a reduced incidence of stroke (-0.0559) and MI (-0.0524). 
RDN was associated with higher incremental costs ($5,951.04) and additional QALYs 
(0.4296) resulting in an incremental cost per QALY of $13,852. Sensitivity analyses 
demonstrated reliability of the base case results across a wide range of assump-
tions. ConClusions: Consideration of both clinical and economic evaluations may 
be necessary to inform reimbursement decision making. Based upon this analy-
sis, RDN is a cost effective treatment option for patients with rHTN in Australia. 
However, this conclusion is dependent upon the magnitude of SBP reduction with 
RDN and assumptions related to long term patient outcomes.
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objeCtives: Hypertension represents a major health problem, affecting more 
than 21% of adults in the Philippines. Amlodipine, a calcium channel blocker, is 
considered to have better tolerance and effectiveness than other classes of anti-
hypertensive treatments. Limited studies have examined the cost-effectiveness of 
Amlodipine in the Philippines. The purpose of this study was to compare the costs 
and effectiveness associated with Amlodipine and Angiotensin II Receptor Blockers 
(Valsartan) in preventing stroke and myocardial infarction (MI) among Filipino 
hypertension patients. Methods: A Markov model was developed using effec-
tiveness, rate of stroke and MI, survival and utility data from published literature. 
Costs of drugs, direct medical costs of hypertension management, stroke/MI treat-
ment, and follow-up management were included. Costs were based on a survey on 
experts in the Philippines except costs of MI treatments, which was retrieved from 
the literature. Total costs and QALYs in a five-year time horizon were calculated and 
compared between Amlodipine and Valsartan. The modeling was conducted with 
10,000 hypertension patients in the Amlodipine and Valsartan arms respectively. 
Discounting rate used for costs and QALYs was 3%. Third-party payer perspective 
was adopted. Results: In the base case analysis, Amlodipine was more effective 
with 30,648.5 QALYs versus Valsartan group’s QALYs which were 30,520.8 (net gain 
was 127.8 QALYs). Amlodipine was less costly with PHP766,083,016 while Valsartan 
group’s costs were PHP2,076,035,008 (costs saved were PHP1,309,951,992). Total cost 
was more sensitive than total QALYs to the sensitivity tests. Changing discount 
rate and cohort age had greater effect on the total cost and QALYs than changing 
the other parameters. However, Amlodipine remained dominant in the different 
scenarios of sensitivity analyses. ConClusions: This modeling analysis suggests 
that Amlodipine achieved overall cost saving and better outcomes when compared 
with ARBs (Valsartan) for hypertension patients in the Philippines.
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objeCtives: Warfarin, the standard oral anticoagulant for stroke prevention in 
patients with atrial fibrillation (AF), is associated with frequent international normal-
ized ratio (INR) monitoring and increased hemorrhagic risk. About 50% of European 
and American AF patients received warfarin nevertheless. Dabigatran, a novel oral 
anticoagulant, had been compared to warfarin to demonstrate its cost-effectiveness 
in developed countries. However, these economic evaluations couldn’t be applied to 
China setting. Despite treatment guidelines, warfarin use was conservative in China 
accounting for only 2.7% AF patients. More than half of the patients (56%) received 
aspirin, and still another 33% did not receive any prophylaxis therapy. In this study, we 
aimed to evaluate the cost-effectiveness of dabigatran in China settings and highlight 
the importance of setting up the right analysis scenarios. Methods: An individual-
level simulation model was developed to project the clinical events and outcomes 
under different treatment pathways over a patient’s remaining lifetime. Three sce-
narios were evaluated. First, aspirin, warfarin, and dabigatran were eligible first-line 
options over no treatment. Second, due to reluctance in warfarin use, only aspirin 
and dabigatran were considered. Third, reluctance in warfarin use together with con-
traindication to aspirin leaved dabigatran the only option. Efficacy/safety data were 
derived from RE-LY trial and published meta-analyses and literature. China-specific 
data were from published studies and expert inputs. Results: In scenario 1, warfarin 
was cost-saving comparing to no-treatment and the ICER for dabigatran versus war-
farin was CNY 367425.7/QALY. Aspirin was dominated. In scenario 2, aspirin was cost-
saving comparing to no-treatment and the ICER for dabigatran versus aspirin was 
CNY 253592.3/QALY. In scenario 3, the ICER for dabigatran versus no-treatment was 
CNY 85436.2/QALY. Given a WTP of CNY 115,261/QALY, conclusions on dabigatran’s 
cost-effectiveness varied in three scenarios. ConClusions: The cost-effectiveness 
of an intervention is not absolute. Country heterogeneity demands careful considera-
tions when setting up the scenarios for analyses.
medical costs of hypertension management, stroke/MI treatment, and follow-up man-
agement were included. All costs inputs were based on either published literature or 
an expert survey. Utility data were retrieved from published literature. Discounting 
rate used for both costs and QALYs was 3% and currency reported in 2014 US dollar 
(US$1 = 30 Taiwanese dollar). Third-party payer perspective was applied. Results: 
Based on the hypothetical cohort of 10,000 hypertension patients, total costs for 
amlodipine and valsartan users were US$7,969,402 and US$13,169,296 respectively. 
Total QALYs was 30,648.5 for amlodipine users and 30,520.8 for valsartan users. 
Compared to valsartan, amlodipine had an incremental cost of -US$5,199,894 with 
127.7 QALYs gained. Results remained consistent from various sensitivity analy-
ses. ConClusions: For hypertension patients in Taiwan, amolodipine is a cost-
saving treatment with better outcomes in preventing stroke and MI in comparison 
with valsartan. It lowers the acute care costs associated with stroke and MI as well 
as costs of follow-up disease management.
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objeCtives: Dyslipidemia is a common chronic disease in China, which is a main 
risk factor for cardiovascular and cerebrovascular diseases. Blood lipid screening is 
a positive method for prevention of dyslipidemia, but the cost-effectiveness of blood 
lipid screening is still unknown. The objective of this study aims to evaluate the cost-
effectiveness of blood lipid screening versus no screening for the primary prevention 
of hyperlipidemia and its complication. Methods: A Markov model was designed 
according to dyslipidemia clinical development and pathway for the cost-effective-
ness analysis. Markov model simulated the long term effects of screening and no 
screening strategies. The model assumed the starting age of 45 and a 30 year horizon. 
All the data for Markov model were extracted from literatures published. The costs 
and benefits were both discounted at 5%. Sensitivity analyses were adopted to explore 
assumptions of the model and to identify which model inputs had most impact 
on the results. Results: The model results showed that the per capita cumulative 
costs and utilities in no screening group were CNY65343 and 12.58 QALYs, and CNY 
64337 and 12.9 QALYs in screening group. Comparing with the no screening group, 
the screening had lower costs and higher utility. The results of One-way sensitivity 
analysis showed that the transition probability from dyslipidemia (no screening) to 
complications, the transition probability from dyslipidemia (screening detected) to 
complications and the cost of drug intervention had obvious impacts on the model 
results. ConClusions: Based on this Markov model, blood lipid screening is likely 
to be cost-effective compared with no screening for the primary prevention of dys-
lipidemia and its complication among Chinese aged 45 and above.
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objeCtives: To determine the cost-effectiveness of catheter-based renal dener-
vation (RDN) for resistant hypertension over a lifetime from the National Health 
Insurance perspective in Korea. Methods: We adopted a Markov state-transition 
model with a monthly cycle which has been developed and validated recently to 
assess clinical and economic impact of replacing ‘standard of care (SOC) alone’ with 
‘SOC plus RDN.’ The model was calibrated to predict the cost-effectiveness of RDN 
in Korean health care setting by best utilizing Korea-specific data for key model 
parameters. Our analysis was based on the Symplicity HTN-2 trial for the changes 
in systolic blood pressure (SBP) at 6 months after RDN treatment. The model incor-
porates 7 clinical endpoints associated with hypertension: hypertension (referring 
to no event), angina pectoris, myocardial infarction, stroke, heart failure, end-stage 
renal diseases, and cardiovascular and non-cardiovascular death (absorbing state). 
A total of 34 health states were defined reflecting all possible health states associ-
ated with the clinical endpoints based on the natural history of diseases. Results: 
According to the base-case analysis, each subject receiving SOC plus RDN to treat 
resistant hypertension gained 0.37 QALYs and 7.21 million Korean won (KRW, one 
US dollar = 1,100 KRW) more than a subject with SOC alone. The incremental cost-
utility ratio (ICUR) was 19.69 million KRW per QALY gained. The results of sensitiv-
ity analyses showed that the relative cost-effectiveness was most sensitive to the 
SBP lowering effect of RDN. Other variables had only minimal impact on results, 
supporting the robustness of the results. ConClusions: ‘SOC plus RDN’ appears 
to be a cost-effective treatment option for patients with resistant hypertension in 
Korea based on the WHO recommendation that a treatment is very cost-effective 
if the treatment’s ICUR is lower than the gross domestic product (GDP) per capita. 
The per-capita GDP in Korea in 2012 was 26 million KRW.
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objeCtives: Catheter-based renal denervation (RDN) is an effective and durable 
therapy option for patients with treatment resistant hypertension (TR-HTN). Based 
on results of the Symplicity HTN-2 trial (NCT00888433), Geisler et al. (2012) devel-
oped a Markov model to quantify the cost effectiveness of RDN plus standard of care 
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Persistence (therapy duration) was defined as number of days between the first and 
last available medication. Adherence was assessed using the medication possession 
ratio (MPR), defined as the number of days with statin therapy on hand divided by 
duration of statin therapy. Results: A total of 3,417 patients met the inclusion 
criteria. The most common statins received were atorvastatin (32.43%), rosuvas-
tatin (22.21%), and pravastatin (20.00%). At initiation, mean(SD) dose (mg/day) was 
9.00(3.66) for atorvastatin, 2.97(1.50) for rosuvastatin, and 9.12(3.09) for pravastatin. 
The percentage of patients with dose titration was low (range: 1.02% for simvastatin 
to 5.01% for rosuvastatin). Mean(SD) persistence ranged from 460.77(270.26) days 
for fluvastatin to 540.08(247.51) days for atorvastatin. Mean(SD) MPR ranged from 
0.90(0.16) for rosuvastatin to 0.95(0.11) for fluvastatin. When MPR was alternatively 
measured over the entire 24 month follow-up period, mean(SD) MPR ranged from 
0.75(0.29) for rosuvastatin to 0.80(0.26) for fluvastatin. ConClusions: Statin titra-
tion among Japanese patients with HRVD was rare, and most patients remained on 
the lowest dosage available during follow-up. Although statin adherence was good, 
these findings raise potential concerns about under-treatment/under-management 
of HRVD in Japan.
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objeCtives: The purpose of this study was to assess patterns and predictors of 
warfarin persistence, discontinuation, and interruption among patients with non-
valvular atrial fibrillation (NVAF). Methods: This study used the MarketScan 
Database and included patients (≥ 18 years of age) with NVAF who were initiated 
on warfarin and followed for 365 days. Persistence was defined as warfarin therapy 
without a gap > 45 days between warfarin prescriptions. Interruption was defined as 
a gap in warfarin therapy > 45 days and ≤ 90 days and discontinuation was defined 
as > 90 days without warfarin therapy. Factors associated with warfarin interrup-
tion/discontinuation were determined using a Cox proportional hazards regres-
sion model. Sensitivity analyses were conducted to assess robustness of results 
by shifting prescription gaps by 7, 14, and 30 days. Results: Within 12 months 
of warfarin initiation, 26,241 (44.8%) patients were persistent with warfarin, 6,895 
(11.8%) had interruption, and 25,457 (43.4%) had discontinuation with or without 
interruption. The risk of warfarin interruption or discontinuation was significantly 
greater in patients that were younger than 65 years (hazard ratio [HR]: 1.22; 95% 
confidence interval [CI]: 1.19-1.25), lived in the West (HR: 1.07; 95% CI: 1.03-1.11), had 
anemia (HR: 1.10; 95% CI: 1.06-1.14), experienced bleeding episodes (HR: 1.10; 95% CI: 
1.06-1.14), were hospitalized or had emergency room visits (HR: 1.11; 95% CI: 1.08-
1.13), or had higher Charlson Comorbidity Index (HR: 1.01; 95% CI: 1.01-1.02). The 
significant factors associated with interruption/discontinuation were consistent 
in the sensitivity analyses. ConClusions: In the usual clinical practice setting, 
more than 50% of patients discontinued or interrupted warfarin within one year 
after initiation. Age < 65 years, multiple medical conditions, and previous hospital 
and ER visits were associated with increased risk of interruption/discontinuation. 
Given the prevalence of warfarin discontinuation/interruption, health care provid-
ers should take a more active role in understanding and addressing the reasons 
behind patient non-persistence.
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objeCtives: The polypharmacy were incidence increase risk of drug-drug interac-
tions, especial suffers from elderly and chronic disease such as age greater than 
60 years old, chronic kidney dysfunction, cardiovascular disease and cancers are 
significant. To evaluate the cost-effectiveness of consultations by pharmacists 
based within primary care polypharmacy in chronic disease. Methods: In order to 
avoid duplication and waste treatment drugs, the plan is to be Pharmaceutical Care 
System and to search medication information at Department of National Health 
Insurance Virtual Private Cloud (VPC). We were identifying potential duplicate medi-
cation from patients with polypharmacy, and to evaluated pharmacist consultations 
on health service use outcome. The study subjects were identified based on inap-
propriate prescriptions of duplicate medications, drug-drug interactions, or over-
dosage. Chi-square test was used for pharmacist consultations on health service 
and cost-effectiveness of data analysis. Results: A total of 68 patients on health 
service with pharmacist consultations were included in this study. The total direct 
medical costs for 24 patients were NT$3,4480 dollars and improved polypharmacy 
related adverse reaction. ConClusions: To develop pharmacist consultations on 
health service is helpful of increase communication and interaction with the pro-
fessional skills of pharmacists and physicians to achieve consensus professional 
and is likely to save costs.
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objeCtives: To determine the quality of life of the patients who underwent angi-
oplasty patients. Methods: This was an open labeled, randomized control trial 
conducted at Kasturba Hospital, Manipal, Karnataka, India. Patients admitted in 
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objeCtives: To study the association between baseline socio-demographic and 
clinical characteristics and total annual follow up cost of unselected patients sub-
jected CRMDs implantation in a real-world setting. Methods: A single-centre, 
prospective study was conducted for one year’s period. In total, 464 consecutive 
patients were recruited (370 were subjected to PM implantation initial or replace-
ment and 94 to ICD implantation initial or replacement). The baseline collected data 
encompasses: socio-demographic characteristics, measurements of anthropometric 
and clinical characteristics; medical history, medications used before the enrolment 
in the study and QoL assessed by the EUROQOL EQ-5D Questionnaire. Resource 
data were assessed at 6 and 12 months after the procedure of implantation. Then, 
the components of cost were calculated using the bottom-up approach. Results: 
The generalized linear model indicated that among the variables considered, only 
age, history of hypertension and hypercholesterolaemia are significantly associ-
ated with the total annual social cost of patients subjected to PM implantation. 
The predicted mean total annual costs (95% CI) adjusted for the factors mentioned 
above were € 2.256 (€ 2.018–€ 2.534) for the overall sample of PM patients, and € 2.171 
(€ 1.888–€ 2.505) and € 2.409 (€ 2.063–€ 2.778) in patients with initial PM implantation 
and those subjected to PM replacement, respectively. In addition, the history of 
hypertension and hypercholesterolaemia as well as the baseline QoL were signifi-
cantly associated with the total annual cost of patients subjected to ICD implan-
tation. The predicted mean total annual costs (95% CI) adjusted for the factors 
mentioned above were € 3.318 (€ 2.771–€ 3.967) for the overall sample of ICD patients, 
and 3.528 (€ 2.901– € 4.156) and € 2.044 (€ 1.329–€ 3.029) in patients with initial ICD 
implantation and those subjected to ICD replacement, respectively. ConClusions: 
Age, history of hypertension and hypercholesterolaemia for the patients were sub-
jected to PM implantation and moreover the quality of life for the patients were 
subjected to ICD are significantly associated with the total annual social cost.
CArdioVAsCUlAr disorders – Patient-reported outcomes & Patient  
Preference studies
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objeCtives: Uncontrolled blood pressure (BP) attributed to medication non-adher-
ence may increase the risk of complications and death. Predicting hypertensive 
patients’ medication adherence, therefore, is an important factor. The theory of 
planned behavior (TPB) proposes that the hypertensive patient’s attitude, subjective 
norm, and perceived behavioral control predict intention to perform behavior, leading 
to prediction of medication adherence. Methods: 604 outpatients with established 
chronic hypertension from a regional hospital in eastern Taiwan were enrolled in this 
study. Using a cross-sectional study, BP was measured and structured questionnaires 
were delivered to all participants. Descriptive statistics were calculated for all meas-
ures as appropriate. To assess differences among the adherence and poor adherence 
groups by demographic, TPB variables and BP, Chi-Square test and Fisher’s exact test 
for categorical variables or analysis of variance tests for continuous variables were 
performed. The medication adherence, TPB variables and BP were analyzed using 
correlation coefficient. All data were analyzed using SPSS 20.0 statistical analysis 
software. Results: The mean of adherence scores was 2.6 (sd= 2.4). Adherence and 
poor adherence of patients accounted for 57.5% and 42.5%, respectively. Intention was 
positively correlated with attitude (r= 0.23, p= 0 .00), subjective norm (r= 0.27, p= 0 .00), 
and perceived behavior control (r= 0.53, p= 0 .00). Adherence was positively correlated 
with intention (r= 0.49, p= 0 .00). When SBP and DBP were considered separately, 
adherence was significantly different between the good and poor controls of SBP and 
DBP. The two adherence groups were positively correlated with SBP control (r= 0.09, 
p= 0 .02) and DBP control (r= 0.10, p= 0.01). ConClusions: Hypertensive patients’ 
attitudes, subjective norms, and perceived behavioral controls predict intentions, 
leading to prediction of medication adherence. Medication adherence has significant 
impact on the SBP and the DBP control. These results suggest that application of TPB 
is useful to predict medication adherence in Taiwanese patients.
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objeCtives: To document dose titration, persistence, and adherence among 
patients with high-risk vascular disease (HRVD) receiving statin therapy in an 
employed Japanese population. Methods: A retrospective analysis was con-
ducted using the Japan Medical Data Center (JMDC) database, which contained 
inpatient, outpatient, and pharmacy claims of 800,000 lives from 2006–2011. HRVD 
was identified based on diagnoses for cerebrovascular disease, peripheral artery 
disease, coronary artery disease with diabetes, and history of acute coronary syn-
drome (ACS) (with an ACS claim > 30–≤ 365 days after ACS-related hospitalization) 
between 1/1/2008–12/31/2009. Patients were required to have insurance coverage 
for ≥ 12 months before and ≥ 24 months after first HRVD claim. Patients receiving 
statin therapy were selected to assess dose titration, persistence, and adherence. 
